Atrasentan in Patients With IgA Nephropathy

A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 404 participants.

Also called NCT04573478

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 404 participants (enrolled count) (from the registry)
Sponsor
  • Novartis Registry lists this organization as the lead sponsor
Registry
  • NCT NCT04573478
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, Argentina, Australia, Brazil, Canada, China, Colombia, France, Germany, Hong Kong SAR China, India, Italy, Japan, New Zealand, Poland, Portugal, South Korea, Spain, Taiwan, United Kingdom (from the registry)
Registry status
  • Active, not recruiting (from the registry)

Technical summary

Registry record NCT04573478. Randomized; double masking; primary purpose treatment. Start 2020-12-11 (actual); primary completion 2028-04-14 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Atrasentan in Patients With IgA Nephropathy
Acronym
ALIGN
Condition
IgA Nephropathy
Condition
Immunoglobulin A Nephropathy
Intervention (Drug)
Atrasentan
Intervention (Drug)
Placebo
Intervention (Drug)
Zigakibart
Lead sponsor
Novartis Pharmaceuticals (class: industry)

Record details

Record id
cardio:ct-nct04573478
Content hash
352918d5bff9c80a5e37b4f0463f0252357d8bc63102df7b8330b532db15f101